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Summary  69 
Background Coronary artery bypass grafting (CABG) is the standard treatment for revascularisation in 70 
patients with left main coronary artery (LMCA) disease, but use of percutaneous coronary intervention (PCI) 71 
for this indication is increasing. We aimed to compare PCI and CABG for treatment of LMCA disease. 72 
 73 
Methods Patients with LMCA disease were enrolled in 36 centres in Northern Europe and randomised 1:1 to 74 
treatment with PCI or CABG. Eligible patients had stable angina pectoris, unstable angina pectoris or non–75 
ST elevation myocardial infarction. The primary endpoint was major adverse cardiac or cerebrovascular 76 
events (MACCE) – a composite of all–cause mortality, non–procedural myocardial infarction, any repeat 77 
coronary revascularisation and stroke. Non–inferiority of PCI to CABG required the lower end of the 95% 78 
confidence interval (CI) not to exceed a hazard ratio (HR) of 1.35 after up to five years of follow–up. 79 
Clinicaltrials.gov identifier: NCT01496651. 80 
 81 
Findings A total of 1201 patients were randomised, 598 to PCI and 603 to CABG, and 592 in each arm 82 
entered analysis by intention to treat. Kaplan–Meier five–year estimates of MACCE were 28·7% for PCI 83 
(121 events) and 20·1% for CABG (81 events), [HR 1·46 (95% CI 1·10–1·95)], exceeding the limit for non–84 
inferiority and was significant for superiority of CABG over PCI (p=0·0079). As-treated estimates were 85 
29·1% vs. 21·1% [HR 1·51 (95% CI 1·15–1·99), p=0·0032].  Comparing PCI to CABG, five–year estimates 86 
were 11·5% vs. 9·5% [HR 1·04 (95% CI 0·65–1·67), p=0·8625] for all–cause mortality; 6·9% vs. 1·9% [HR 87 
2·9 (95% CI 1·40–5·90), p=0·000] for non–procedural myocardial infarction; 16·2% vs. 10·4% [HR 1·5 88 
(95% CI 1·04–2·17), p=0·0315] for any revascularisation; and 4·9% vs. 1·7% [HR 2·3 (95% CI 0·92–5·48), 89 
p=0·0731] for stroke.  90 
 91 
Interpretation The findings of this study indicate that CABG may be superior to PCI for treatment of left 92 
main stem coronary artery disease. 93 
 94 
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Funding Biosensors, Aarhus University Hospital, and participating sites 95 
 96 
Word count: 311 97 
 98 
Introduction 99 
Treatment of unprotected left main coronary artery (LMCA) disease using percutaneous coronary 100 
intervention (PCI) has increased rapidly during the past decade, following the favourable results of 101 
randomised trials1–4 and observational registry studies comparing PCI and coronary artery bypass grafting 102 
(CABG).5–9 At the present time, both options are used to treat LMCA disease.10 Current guidelines 103 
recommend PCI in LMCA patients with coronary pathology favourable to PCI, i.e., in the absence of 104 
complex and diffuse lesions.10 The guidelines are based primarily on the pre specified, and powered 105 
subgroup of 705 patients with LMCA disease in the SYNTAX trial,11-12 which compared PCI with the drug–106 
eluting Taxus stent to CABG in patients with 3–vessel or LMCA disease. The guidelines also refer to the 107 
findings of the randomised LE MANS,1 PRECOMBAT2 and Boudriot et al.3 trials, which included 105, 600 108 
and 201 patients with LMCA stenosis, respectively. In the randomised trials, the non–inferiority margin was 109 
wide, due to relatively small patient sample sizes and thus the trials were not powered to definitively 110 
determine the best treatment for unprotected LMCA disease. 111 
In the NOBLE trial we hypothesized that PCI with drug–eluting stents would produce non–112 
inferior clinical results compared with CABG in revascularisation of 1200 patients with unprotected LMCA 113 
stenosis. 114 
 115 
Methods 116 
Study design 117 
The Nordic–Baltic–British Left Main Revascularisation Study (NOBLE) trial, a prospective, randomised, 118 
open label, clinical, non-inferiority trial was conducted at 36 sites in Latvia, Estonia, Lithuania, Germany, 119 
 6 
Norway, Sweden, Finland, United Kingdom and Denmark. The authors designed the study, wrote the 120 
manuscript and vouch for the completeness and accuracy of data collection and analysis. The protocol and 121 
consent forms were consistent with Good Clinical Practice, the Declaration of Helsinki and all relevant 122 
regulations. The study was approved by The Central Denmark Region Committees on Health Research 123 
Ethics, and by national or local ethics committees for the individual sites as appropriate, and by the Danish 124 
Data Protection Agency. The trial was registered with ISRCTN87206264 and clinicaltrials.gov identifier: 125 
NCT01496651. 126 
 127 
Patient selection  128 
A local interventional cardiologist and a cardiac surgeon at each site prospectively evaluated eligible patients 129 
with LMCA disease. Inclusion criteria for study enrolment were stable angina pectoris, unstable angina 130 
pectoris or acute coronary syndrome, together with a significant lesion (visually assessed stenosis diameter 131 
>50% or fractional flow reserve ≤0·80) of the LMCA ostium, mid–shaft and/or bifurcation and with no more 132 
than three additional non–complex lesions. Complex lesions were defined as chronic total occlusions, 133 
bifurcation lesions requiring two stent techniques or lesions with calcified or tortuous vessel morphology. 134 
Exclusion criteria were ST–elevation infarction within 24 hours, patient considered too high risk for CABG 135 
or PCI, or expected survival <1 year. Patients were enrolled in the study by site investigators or designated 136 
staff. A screening log was maintained in 5 centres which recruited 506 of the 1201 patients. All enrolled 137 
patients provided written informed consent. 138 
 139 
Randomisation and masking 140 
Patients for whom it was determined that equivalent revascularisation could be achieved with CABG or PCI 141 
were randomly assigned (1:1) to undergo either treatment.  Randomisation was performed by a web based 142 
computer randomization system (Trialpartner, random allocation sequence generated by Jakob Hjort, 143 
Institute of Clinical Medicine, Aarhus University, Denmark) in permutated blocks by country and centre 144 
with stratification by gender, presence of a distal LMCA bifurcation lesion, and presence of diabetes 145 
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mellitus. Patients were assigned to the allocated treatment according to randomization by site investigators. 146 
Still, the actual operator could overrule the assignment if the patient was found not to be eligible for the 147 
allocated treatment or if the patient refused to undergo the allocated treatment. The study was not blinded. 148 
 149 
Revascularisation and pharmacologic treatment 150 
Patients were treated with the intention of achieving complete revascularisation of all vessels with significant 151 
lesions. In the PCI group, ostial and mid–shaft lesions were treated with a single stent. Distal bifurcation 152 
lesions could be treated with two–stent techniques, preferably the culotte technique. Mini crush, T–stenting, 153 
V–stenting or a single–stent strategy could be used if appropriate to lesion morphology and the operator’s 154 
experience. High–pressure post–dilatation after stent implantation was recommended for all cases. Final 155 
kissing balloon dilatation was encouraged after main–vessel–only stenting and was mandatory when a two–156 
stent technique was used. Intravascular ultrasound (IVUS) was strongly recommended pre– and post–stent 157 
deployment. Use of drug–eluting stents was mandatory. In March 2010, after treatment of 73 patients with 158 
PCI, the Biolimus–eluting stent (Biomatrix Flex, Biosensors, Switzerland) became the recommended study 159 
stent. 160 
Patients randomised to the CABG group were treated according to current clinical practice. 161 
The left internal mammary artery was recommended for revascularisation of the left anterior descending 162 
coronary artery, whenever feasible. For other lesion locations, saphenous venous grafts, free arterial grafts or 163 
the right internal mammary artery could be used. 164 
After the index procedure, patients were treated according to local practice. Treatment 165 
included 75–150 mg of aspirin lifelong. In both arms, patients with acute coronary syndrome received 75 mg 166 
clopidogrel daily for 12 months. All PCI patients also received 75 mg clopidogrel daily for 12 months. 167 
Prasugrel or ticagrelor could be substituted for clopidogrel at the discretion of the operator. 168 
 169 
Primary endpoint 170 
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The primary endpoint was a composite of major adverse cardiac and cerebrovascular events [(death from any 171 
cause, non–procedural myocardial infarction13, repeat revascularisation or stroke) (MACCE)]. The main 172 
hypothesis was non–inferiority of PCI to CABG, assessed as the lower limit of the 95% CI of the hazard 173 
ratio (HR) of PCI to CABG, not exceeding 1·35 assessed at median three years follow-up.  174 
 175 
Summary of change to the primary endpoint 176 
The original primary endpoint was evaluation of non-inferiority of PCI to CABG assessed by MACCE at full 177 
two years follow-up. Due to low event rates the primary endpoint assessment was primo 2015 changed to a 178 
median follow-up including all MACCE endpoints up to five years follow-up and timing of evaluation when 179 
the originally stipulated 275 primary endpoint events were reached.  Ultimo 2015 it was forecasted that the 180 
275 events would not be reached within full five years follow-up, and the primary endpoint assessment was 181 
changed to median 3 years. See Supplementary Appendix for detailed information.  182 
 183 
Secondary endpoints 184 
Other clinical endpoints were the individual components of the primary MACCE endpoint, definite stent 185 
thrombosis and symptomatic graft occlusion. Procedural myocardial infarctions were documented (post hoc). 186 
Repeat revascularisations were categorized as target lesion revascularisation, LMCA target lesion 187 
revascularisation or de novo lesion revascularisation. Functional class was reported as maximal New York 188 
Heart Association (NYHA) score and chest pain was reported by the maximal Canadian Cardiovascular 189 
Society (CCS) score at up to five years follow-up.  190 
Angiographic evaluation 191 
Diagnostic angiograms were reviewed an independent core laboratory [European Cardiovascular Research 192 
Center (CERC), France] who were blinded to the assigned treatment. Diagnostic angiograms were scored 193 
according to the SYNTAX I score algorithm at both the recruitment sites and the core laboratory.14  194 
 195 
 196 
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Clinical endpoint adjudication 197 
An independent clinical events committee consisting of cardiologists and a cardiac surgeon adjudicated all 198 
possible events concerning cause of death, stroke, myocardial infarction, revascularisation, graft occlusion, 199 
and stent thrombosis. (See Supplementary Appendix for list of members). 200 
 201 
Data and Safety Monitoring Board 202 
The study was overseen by an independent Data and Safety Monitoring Board, which received information 203 
on clinical events. (See Supplementary Appendix for list of members). 204 
 205 
Sample size 206 
The sample size calculation was based on estimated occurrence of the composite primary endpoint of 207 
MACCE after mean follow–up of two years. A HR of 1·36, comparing PCI and CABG at one year, was 208 
derived from the SYNTAX trial,11-12 and translated into 30% of PCI patients and 23% of CABG patients 209 
experiencing MACCE after two years of follow–up. A HR of 1·35 were defined accordingly as the clinical 210 
acceptable non–inferiority limit not to be exceeded by the on-sided 95% confidence interval (CI). This 211 
corresponded to a total of 275 events, with 1200 patients, 600 in each treatment group, required to detect 212 
non–inferiority of PCI to CABG at two-years follow-up. As the total number of events could not be reached 213 
within the full five–year follow–up period for MACCE, the primary endpoint was assessed at a median of 214 
three years of follow–up. (See Supplementary Appendix for details of sample size calculation and changes to 215 
the primary endpoint reporting). 216 
 217 
Statistics 218 
The intention–to–treat principle was used in the analysis if not specified otherwise. Continuous variables 219 
were reported as means ± standard deviations (SDs) and compared by t–test if they followed a Gaussian 220 
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distribution. Continuous variables not following a Gaussian distribution were reported as their median value 221 
and interquartile range [IQR] and compared using the Mann–Whitney test. Binary variables were reported as 222 
counts and percentages, and baseline and in–hospital differences between the two groups were assessed 223 
using the Chi–square or Fisher's exact test if a cell value was lower than 5. Follow–up began at 224 
randomisation. In the analysis of individual endpoints, follow–up continued until the date of a clinical 225 
endpoint event, death, emigration, or five years after randomisation, whichever occurred first. All patients 226 
were followed for at least one year. Clinical outcomes occurring during the 30 days following the index 227 
procedure and at 12 months were presented with risk differences (RDs) and compared using the log–rank 228 
test. Extended follow–up to five years was reported using 5–year Kaplan–Meier estimates and HRs with 229 
95% CIs computed on unadjusted Cox regression analysis. Cumulative rates of major adverse cardiac or 230 
cerebrovascular events were stratified into three groups based on the core laboratory SYNTAX score (“low”: 231 
≤22; “intermediate”: 23 to 32; and “high”: ≥33), and presented by Kaplan–Meier curves. A p value <0·05 232 
was considered significant. All analyses were performed using STATA12. 233 
  234 
Role of the funding source 235 
Aarhus University Hospital was the main sponsor of the trial. Biosensors provided an institutional 236 
research grant for the trial but had no role in the study design; in the collection, analysis, and 237 
interpretation of the data, in the writing of this report; or in the decision to submit the paper for 238 
publication. The corresponding author, NRH and HTS had full access to all the data in the study 239 
and had together with the Writing group (see supplementary material) the final responsibility for the 240 
decision to submit for publication.  241 
 242 
Results 243 
A total of 1201 patients were enrolled from Dec 2008 to Jan 2015 in 36 centres. Fourteen withdrew consent, 244 
three were lost to follow–up and 1184 were included in the analysis (592 patients in each group, figure 1). 245 
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Patients were followed for at least one year and extended follow–up was available for a median of 3·1 [IQR: 246 
2·0:5·0] years. Follow–up for the primary endpoint was continued until May 1st 2016 and was available for 247 
89.7% and 89.9% of the study population at two years, 68.8% and 67.2% at three years, 52.0% and 49.5% at 248 
four years, and 37.8% and 35.1% at five years in the PCI and CABG arm respectively, corresponding to 69% 249 
of the total study follow-up completed.  250 
 251 
Baseline characteristics 252 
In the PCI and CABG groups, median ages were 66·2±9·9 years and 66·2±9·4 years (p=0·91), female were 253 
116 (19·6%) and 140 (23·7%) (p=0·0902) and patients with diabetes were 86 (14·6%) and 90 (15·2%) 254 
(p=0·9410), respectively. The logistic EUROSCORE was 2[IQR 2:4] (p=0.1884) in both groups and the 255 
SYNTAX scores were 22·3±7·8 and 22·4±7·4 (p=0·7062) in the PCI and CABG groups, respectively. The 256 
procedure indication was stable angina pectoris or silent ischemia in 466 (78·7%) of patients in the PCI 257 
group and 476 (80·5%) in the CABG group (p=0·4358). Distal LMCA disease was present in 477 (80·8%) 258 
of patients in the PCI group and 482 (81·4%) of patients in the CABG group (p=0·7111). Additional 259 
characteristics of the study population are provided in table 1. 260 
 261 
PCI procedural characteristics 262 
Among PCI–treated patients (Supplementary table 1), 312 (53·4%) had isolated LMCA treatment, 191 263 
(32·5%) had one additional lesion treated, and 55 (9·6%) had two additional lesions treated. LMCA 264 
treatment involved the bifurcation in 508 (87·7%) of PCI cases and two–stent techniques were applied in 176 265 
(34·6%) of LMCA bifurcation treatments. A first–generation drug–eluting stent was implanted in the LMCA 266 
in 10·9% of PCI cases. The nominal diameter of stents in the LMCA was 4·0 [IQR 4·0:4·5] mm, inflated to 267 
18 [IQR16:20] atm. Kissing balloon inflation was performed in 277 (54·5%) and any ostial circumflex post–268 
dilatation was performed in 79·8% of LMCA bifurcation treatments. Complete revascularisation was 269 
achieved in 543 (93·6%) of cases. IVUS of the LMCA was performed pre–PCI in 270 (46·3%) and post–PCI 270 
in 430 (74·1%) of PCI treated patients. 271 
 272 
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CABG procedural characteristics 273 
CABG was performed using the on–pump technique in 476 (84·4%) patients, 526 (93·4%) underwent 274 
arterial grafting of the left anterior descending artery and 480 (85·7%) underwent left internal mammary 275 
artery plus venous grafting. Grafting using the right internal mammary artery was performed in 44 (7·9%) 276 
cases. The number of grafts per patient were one in 23 (4·1%) patients; two in 294 (52·0%) of patients; three  277 
in 220 (39·0%) of patients; four in 25 (4·4%) of patients; and 5 in 3 (0·6%) of patients (Supplementary table 278 
2). 279 
 280 
Primary endpoint 281 
Kaplan–Meier estimates of MACCE by intention-to-treat after five years were 28·7% (121 events) for PCI 282 
and 20·1% (81 events) for CABG (figure 2). The HR was 1·46 (95% CI 1·10–1·95), exceeding the limit for 283 
non–inferiority (1·35), and was significant for superiority of CABG compared to PCI (p=0·0079). Notably, 284 
one–year rates of MACCE in the two groups were the same [7·1% (42) vs. 7·1% (42), (RD 0·0, 95% CI –285 
2·9–2·9, p=1·00)]. Outcome by actual treatment was 28·1% (120 events) vs. 19·2% (78 events), HR 1·46 286 
(95% CI 1·10–1·95), p=0.0032.   287 
 288 
Secondary clinical endpoints 289 
Five–year risk estimates comparing PCI to CABG (table 2) were 11·5% (36) vs. 9·5% (33) [HR 1·04 (95% 290 
CI 0·65 –1·67), p=0·8625] for all–cause mortality; 6·9% (29) vs. 1·9% (10) [HR 2·9 (95% CI 1·40–5·90), 291 
p=0·0040] for non–procedural myocardial infarction; 4·9% (16)vs. 1·7% (7) [HR 2·3 (95% CI 0·92–5·48), 292 
p=0·0731] for stroke (all were ischemic), 16·2% (71) vs. 10·4% (47) [HR 1·5 (95% CI 1·04–2·17), 293 
p=0·02315] for total repeat revascularisation; 10·0% (41) vs. 7·5% (33) [HR 1·2 (95% CI 0·78–1·94), 294 
p=0·3714] for repeat revascularisation of the LMCA; and 6·2% (24) vs. 2·6% (11) [HR 2·3 (95% CI 1·16–295 
4·74), p=0·00180] for de–novo lesion revascularisation during follow–up. Maximal NYHA score at up to 296 
five years follow-up was 1 in 57% and 54%, 2 in 37% and 36%, 3 in 5% and 10%, and 4 in 1 and 0.2% 297 
(p=0.0110), further was CCS class during up to 5 years follow-up 0 in 42% and 50%, 1 in 41% and 35%, 2 298 
in 14% and 13%, 3 in 3% and 2%, 4 in 1% and 1% (p=0.0932) in PCI and CABG, respectively. 299 
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 300 
30–day outcomes following the index procedure 301 
Rates of outcomes, comparing the PCI group to the CABG group, during the 30 days following the index 302 
procedure were; 16 (5·4%) vs. 16 (6·7%) [RD –1·3% (95% CI–5·4–2·8), p=0·5238] for procedural 303 
myocardial infarction (assessable in 238 (41·8%) and 296 (50.6%) of patients), 1 (0·2%) vs. 23 (3·9%) [RD 304 
–3·7% (95% CI–5·3––2·1), p<0·0001] for reoperation for bleeding, 11 (2·0%) vs. 150 (27·5%) [RD –25·4% 305 
(95% CI –29·3––21·5), p<0·0001] for blood transfusion, 0 (0·0%) vs. 3 (0·5%) [RD –0·5% (95% CI –1·1–306 
0·07), p=0·0825] for surgery for a sternum infection, and 2 (0·4%) vs. 4 (0·7%) [RD 0·3% (95% CI –1·2–307 
0·5), p=0·4162] for surgery to address access site complications. The duration of the index treatment 308 
admission was 2 [IQR 1:4] days for PCI and 9 [IQR 7:13] (p<0·0001) days for CABG. Comparing the PCI 309 
group to the CABG group, rates of 30 days all–cause mortality were 2 (0·3%) vs. 7 (1·2%) [RD –0·8% (95% 310 
CI –1·8–0·1), p=0·0943], rates of non–procedural myocardial infarction were 3 (0·5%) vs. 0 (0·0%) [RD 0·5 311 
(95% CI –0·06–1·1), p=0·0829], rates of revascularisation were 7 (1·2%) vs. 10 (1·7%) [RD –0·5% (95% CI 312 
–1·8–0·8), p=0·4636] and rates of stroke were 0 (0·0%) vs. 0·4% [RD –0·7% (95% CI –1·3––0·01), 313 
p=0·0451], respectively (table 3). 314 
 315 
One–year clinical outcomes 316 
One–year clinical outcomes are shown in table 4. One–year outcome comparing the PCI group to the CABG 317 
group were 9 (1·5%) vs. 17 (2·9%) [RD –1·3% (95% CI –3·0–0·3), p=0·1126] for all–cause mortality; 8 318 
(1·4%) vs. 13 (2·2%) [RD –0·8 (95% CI –2·3–0·6), p=0·2709] for cardiac death, 11 (1·9%) vs 8 (1·4%) [RD 319 
0·5 (95% CI –0·9–1·9) for non–procedural myocardial infarction, p=0·4878], 2 (0·3%) vs. 6 (1·0%) [RD –320 
0·7% (95% CI –1·6–0·3), p=0·1559] for stroke, and 32 (5·4%) vs. 24 (4·0%) [RD 1·4 (95% CI –1·1–3·8), 321 
p=0·2734] for total repeat revascularisation. 322 
 323 
Outcomes according to SYNTAX score groups 324 
Comparing the PCI group to the CABG group, five–year Kaplan–Meier estimates for MACCE in the 325 
SYNTAX score subgroups were as follows: “low” 1–22: 29·7% (57 of 297) vs. 16·2% (33 of 316) [HR 1·85, 326 
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95% CI (1·20–2·85), p=0·0050, 51·8% of study population]; “intermediate” 23–32: 27·1% (52 of 249) vs. 327 
21·9% (37 of 220) [HR 1·16, 95% CI (0·76–1·78), p=0·4763, 39·6% of study population], and “high” >32: 328 
32·9% (12 of 46) vs. 23·6% (11 of 56) [HR 1·41, 95% CI (0·62–3·20), p=0·4099, 8·6% of study population] 329 
(figure 3).   330 
 15 
Discussion 331 
The EXCEL and NOBLE studies are the largest international randomised studies comparing PCI and CABG 332 
in the treatment of LMCA disease to date.15 The key findings of the NOBLE study are (1) CABG was 333 
superior to PCI for the composite endpoint of MACCE, (2) all–cause mortality was similar in the two 334 
groups, (3) non–procedural myocardial infarction and need for repeat revascularisation were increased after 335 
PCI, (4) a higher rate of stroke was observed in the CABG group after 30 days, but an unexpected, 336 
numerically higher rate of stroke was found among PCI patients in 5–year estimates, (5) maximal angina 337 
pectoris score was higher after PCI at up to 5 years follow-up (6) the differences in outcomes were seen 338 
mainly after one year of follow–up, and (7) the SYNTAX score was not associated with MACCE after PCI. 339 
 340 
The composite primary MACCE endpoint was similar in NOBLE and the SYNTAX trial except NOBLE did 341 
not include peri-procedural myocardial infarction. We found no difference in large peri-procedural 342 
myocardial infarctions between PCI and CABG in NOBLE, and similar to NOBLE, no difference was 343 
observed at one year in the SYNTAX trial comparing the PCI group to the CABG group (MACCE: 13·7% 344 
vs. 15·8%, p=0·44).12 At five year follow-up in the SYNTAX trial, the MACCE rate was higher in the PCI 345 
group compared to the CABG group (36·9% vs. 31·0%, p=0·12).16 A recent meta-analysis of the SYNTAX 346 
LMCA subgroup and PRECOMBAT17 showed that PCI was associated with significantly higher MACCE 347 
after 5 years (28·3% vs. 23·0%, p=0·045), as confirmed by the NOBLE trial. 348 
 349 
Our findings of similar mortality but higher rates of myocardial infarction and repeat revascularisation in 350 
patients undergoing PCI compared to CABG are consistent with previous major studies of coronary 351 
revascularisation in patients with LMCA disease.1–4,16-17 The low mortality following treatment in both 352 
groups demonstrates that modern revascularisation techniques and adjunctive therapy can lead to excellent 353 
survival in stable LMCA patients. Still, the increased rates of non–procedural myocardial infarction, repeat 354 
revascularisation and stroke associated with PCI are important considerations in selecting optimal treatment 355 
for individual patients.   356 
 16 
 357 
The reason for the increase in myocardial infarctions during follow–up after PCI may be multifactorial, as 358 
both target lesion–related myocardial infarctions and de–novo lesion myocardial infarctions were 359 
contributory. The main advantage of CABG may be bypassing of long lesion segments by grafting, which 360 
protects to a greater extent against target lesion myocardial infarctions and proximal de–novo lesion 361 
myocardial infarctions. Although the increased rate of myocardial infarctions after PCI did not translate into 362 
differences in cardiac deaths, all reported myocardial infarctions were diagnosed during symptom–driven 363 
hospitalizations, signalling a disadvantage for the patient.   364 
 365 
Maximal angina pectoris score was higher after PCI than after CABG probably contributing to the increased 366 
revascularisation rates in the PCI group. Increased revascularisation rates after PCI compared to CABG are 367 
consistent with previous publications on both LMCA stenting1–9 and three–vessel coronary artery disease 368 
stenting.4,18 Although restenosis of drug–eluting stents has diminished over time with introduction of high–369 
pressure deployment,19 use of IVUS,20and improved stent design,21 it remains a weakness of PCI for 370 
treatment of LMCA disease. This may again reflect the superiority of “bypassing” the lesion territory as well 371 
as segments with potentially progressive disease. Accordingly, we found a small difference in target LMCA 372 
revascularization but a more than two-fold increase in the need for de–novo lesion revascularisation in the 373 
PCI group compared with the CABG group during follow–up. Repeat revascularisation was performed 374 
mainly using PCI, but an estimated 4·4% of PCI patients required revascularisation using CABG during the 375 
up to five years of follow–up. As no angiographic follow–up was performed, rates of asymptomatic graft or 376 
stent failure are unknown. 377 
 378 
Stroke rates were remarkably low in this study, especially during the first 30 days post–procedure. During 379 
follow–up, stroke rates in the surgical cohort remained almost static, whereas in the PCI group, the very low 380 
early procedural stroke rate (0·0%) gradually increased over time to an estimated 4·9% at five years. These 381 
findings contrast with previous studies, which have tended to show a higher stroke rate for CABG, persisting 382 
at long-term follow-up in the 5-year report of the SYNTAX LMCA trial, whereas the differences in stroke 383 
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rates were limiting at longer follow-up in the other randomised trials.. All strokes were ischemic with no 384 
clear explanation for the rate among PCI patients. The strokes in the PCI arm mainly occurred after one year, 385 
coinciding with termination of dual antiplatelet inhibition treatment. Still, the low number of strokes and the 386 
late separation of the stroke event curves do not exclude that this finding was due to chance. 387 
 388 
The SYNTAX score was not associated with outcomes after PCI in contrast to the SYNTAX study.11,16  The 389 
unexpected finding of a substantial better outcome after CABG in the low SYNTAX score group could be 390 
the result of the fact that 87% of PCI treatments involved the LMCA bifurcation which is known to predict 391 
worse outcome. This may therefore represent a limitation of the SYNTAX score for treatment selection in 392 
patients with LMCA disease. The clinical utility of the SYNTAX score may be better in patients with 393 
multivessel disease, based on whom the score was developed. 394 
 395 
Thirty–day outcomes were noteworthy. The death rate among patients treated with PCI was only 0·3%, 396 
compared to 1·2% among patients undergoing CABG. Only 1·2% of PCI patients and 1·7% of CABG 397 
patients required repeat revascularisation during the first 30 days post–procedure. Disadvantages of CABG 398 
manifested during early follow–up, with a 3·9% reoperation rate for bleeding, a 0·5% reoperation rate for 399 
sternum infection, and a 27·5% rate of blood transfusion. The median hospitalization period – 2 days for PCI 400 
and 9 days for CABG – represented a significant difference between the revascularisation modalities. 401 
 402 
While MACCE was exactly the same for the two treatment groups at one year, there was a significant 403 
difference in the long term outcomes between the PCI and CABG groups. This suggests that selecting PCI 404 
over CABG can be justified in patients with reduced life expectancy. However our data clearly show that the 405 
practice of only reporting event rates at one year22 in PCI revascularisation trials is not reliable for predicting 406 
long–term prognosis. 407 
 408 
In terms of surgical technique, the majority of CABG patients received one or more arterial grafts. While 409 
high long–term patency of the internal mammary artery is expected,23 some vein graft degeneration can be 410 
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expected beyond five years.21 We will follow all patients for MACCE for a full five years and for all–cause 411 
mortality for ten years.   412 
 413 
Among PCI patients, the vast majority had bifurcation LMCA involvement, consistent with previous 414 
studies.11 A single–stent provisional approach was used for two–thirds of patients, and one–third underwent 415 
dual stenting, chiefly with the culotte technique. Half of patients underwent a kissing balloon procedure. The 416 
optimal stent implantation technique in LMCA is unknown,25 but adequate expansion and full lesion 417 
coverage are required.26 IVUS can be helpful in this regard, but less than half of PCI patients had a pre–PCI 418 
IVUS assessment and 75% had a post–PCI IVUS assessment. Detailed analysis of the IVUS data and 419 
stenting techniques may improve our understanding of implantation results in this trial. The majority of 420 
patients with LMCA disease have diameters above 4 mm (average 5·7 mm) indicating the requirement for 421 
post dilatation beyond the nominal diameter.27 Bench testing of the 3·5 and 4·0 mm BioMatrix stent (similar 422 
platform) showed the ability to expand to 5·9 mm.28 Larger left mains were possibly excluded by the local 423 
cardiac  teams. The majority had post–dilatation of the LMCA but only half of the patients had post–424 
dilatation with balloons larger than 4 mm. Stent under–expansion and mal–apposition in the LMCA may 425 
have contributed to the numerically higher target LMCA revascularisations in the PCI group.  426 
 427 
The NOBLE results should be generalized with caution and in particular the SYNTAX stratified results as 428 
they are rather different from previous publications. The change to the primary endpoint timing is a major 429 
limitation but was carefully considered by investigators and statisticians in response to the low event rates to 430 
avoid a vastly underpowered and likely inconclusive primary non-inferiority endpoint reporting. The 431 
reporting by Kaplan-Meier estimates could be influenced by a change in risk for those entering the study 432 
early and late as will be determined at the full five-year follow-up. Still, the main five-year KM outcome 433 
estimates in NOBLE are in line with the results presented in the recent metaanalysis of 5-year outcome in the 434 
SYNTAX LMCA and PRECOMBAT trials.17 As patients in NOBLE were elective or stabilized patients 435 
results may not be applicable in the acute setting where PCI may be preferred over CABG if the anatomy is 436 
suitable for PCI. The centres in the trials were selected according to interest in LMCA and bifurcation 437 
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treatment and the result might not be translated into centres with low volume in bifurcation treatment. A 438 
small fraction of patients were treated with first generation drug eluting stents and the study stent had a strut 439 
thickness above most types of presently used permanent metallic stents. Still, the study stent is a proven 440 
device with good clinical results in general use29,30 and it is therefore uncertain if the applied stent types 441 
affects the generalizability of the results.   442 
     443 
 444 
The primary endpoint of this study clearly favoured surgical revascularisation. However, it was a composite 445 
endpoint, and the results may be interpreted in various ways. We saw a slight difference in patients refusing 446 
the allocated treatment in favor of PCI and in some patients’ view, the need for surgery, the long 447 
hospitalization, the risk of reoperation for bleeding and infection, and a longer recovery time may not be 448 
worth the lower risk of repeat revascularisation and myocardial infarction, as no difference in all–cause 449 
mortality was found. 450 
 451 
In conclusion, the NOBLE trial showed that CABG may provide a superior clinical outcome for treatment of 452 
LMCA disease compared to PCI. 453 
 454 
  455 
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Research in Context 499 
Evidence before this study 500 
We searched PubMed reports on randomised trials comparing percutaneous coronary intervention (PCI) with 501 
coronary artery bypass grafting (CABG) in treatment of left main coronary artery (LMCA) disease with the 502 
search terms “percutaneous coronary intervention”, “coronary artery bypass operation”, “coronary artery 503 
bypass grafting”, “randomised”, or “randomized”, published after the introduction of drug eluting stents, 504 
between January 1, 2003, and September 1st, 2016. We identified four randomised trials1–3,16. Three trials 505 
were underpowered for clinical end-points1-3 and in the SYNTAX trial16, included only 705 patients with 506 
LMCA disease. Although, the randomised trials suggested that PCI was a valid alternative to CABG, we 507 
found a need for further documentation with a large randomised trial. 508 
 509 
Added value of this study 510 
Our findings of similar mortality but higher rates of myocardial infarction and repeat revascularisation in 511 
LMCA patients undergoing PCI compared to CABG are consistent with the previous randomised studies1–512 
3,16. With 1201 patients included in our study the increased rates of major adverse cardiac or cerebrovascular 513 
events (MACCE) associated with PCI beyond one year became significant, and confirms a recent 514 
metaanalysis also showing increased MACCE after PCI at five years. 17 Contrasting to the SYNTAX trial16, 515 
our study suggested that patients with LMCA disease had inferior outcome after PCI compared to CABG 516 
irrespective of coronary lesion complexity evaluated with the SYNTAX score.14  517 
 518 
Implications of all the available evidence 519 
Despite similar mortality, the 5-year risk of MACCE is higher after PCI compared to CABG for treatment of 520 
unprotected LMCA disease.   521 
 522 
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 PCI CABG P–value 
Age (yrs) 66·2±9·9 66·2±9·4 0·91 
Gender (female) 116 (19·6%) 140 (23·7%) 0·09 
BMI (kg/m2) 27·9±4·5 28·1±4·4 0·53 
Diabetes type I or type II 86 (14·6%) 90 (15·2%) 0·94 
Family history of IHD 321 (57·9%) 307 (55·7%) 0·45 
Statin treatment 482 (81·6%) 464 (78·4%) 0·17 
Hypertension 386 (65·4%) 389 (65·7%) 0·91 
Active smoking 108 (18·5%) 127 (21·6%) 0·18 
Previous PCI 116 (19·7%) 118 (20·0%) 0·90 
Previous CABG 4 (0·68%) 2 (0·34%) 0·41 
Ejection fraction (% [IQR]) 60 [55;65] 60 [52;64] 0·27 
NYHA class     
  I 244 (52·8%) 195 (42·6%)  
  II 135 (29·6%) 150 (33·1%)  
  III 57 (12·5%) 77 (17·0%)  
  IV 23 (5·0%) 33 (7·3%) 0·0120 
EUROSCORE 2 [2:4] 2 [2:4] 0·18 
SYNTAX score 22·5±7·5 22·4±8·0 0·74 
Indication     
  Stable angina pectoris 466 (78·7%) 476 (80·5%) 0·61 
  Unstable angina pectoris 106 (17·9%) 100 (16·9%) 0·65 
Lesions to be treated (n [IQR]) 2[1:3] 2[2:3] <0·0001 
Distal LMCA lesion 477 (80·8%) 482 (81·4%) 0·77 
Table 1.  Baseline characteristics by treatment group 
BMI: body mass index; IHD: ischemic heart disease; NYHA class: New York Heart Association class; 619 
LMCA: left main coronary artery 620 
 28 
 PCI CABG Hazard ratio 95% CI P–value 
All–cause mortality 36 (11·5%) 33 (9·5%) 1·04 0·65–1·67 0·86 
Cardiac death 14 (3·1%) 15 (3·1%) 0·86 0·41–1·81 0·69 
Vascular death 2 (0·7%) 1 (0·2%) 1·96 0·18–21·66 0·55 
Non–procedural MI 29 (6·9%) 10 (1·9%) 2·88 1·40–5·90 0·0040 
Revascularisation (total) 71 (16·2%) 47 (10·4%) 1·50 1·04–2·17 0·0232 
Revascularisation with PCI 56 (12·9%) 45 (10·1%) 1·23 0·83–1·83 0·29 
Revascularisation with CABG 19 (4·4%) 2 (0·3%) 9·41 2·20–40·38 0·0031 
Target lesion revascularisation 50 (11·7%) 36 (8·0%) 1·38 0·90–2·12 0·14 
Target LMCA revascularisation 41 (10·0%) 33 (7·5%) 1·23 0·78–1·94 0·37 
De–novo lesion revascularisation* 24 (6·2%) 11 (2·6%) 2·34 1·16–4·74 0·0180 
Symptomatic graft occlusion or definite stent 
thrombosis  
9 (2·6%) 15 (4·1%) 0·59 0·26–1·36 0·22 
Possible stent thrombosis 4 (1·3%) 0 (0·0%) – – – 
Probable stent thrombosis 2 (0·3%) 0 (0·0%) – – – 
Stroke 16 (4·9%) 7 (1·7%) 2·25 0·92–5·48 0·07 
Table 2. Kaplan–Meier five–year estimates by intention–to–treat 
* New lesion in non–stented segment or non–grafted vessel.   621 
 622 
  623 
 29 
 624 
 PCI CABG Risk difference 95% CI P–value 
Death 2 (0·3%) 7 (1·2%) –0·8% –1·8–0·1 0·09 
Cardiac death 2 (0·3%) 7 (1·2%) –0·8% –1·8–0·1 0·09 
Vascular death 0 (0·0%) 0 (0·0%) 0·0% – 1·00 
Procedural MI* 16 (5·4%) 16 (6·7%) –1·3% –5·4–2·8 0·40 
Non–procedure–related MI 3 (0·5%) 0 (0·0%) 0·5% –0·06–1·1 0·08 
Definite stent thrombosis or symptomatic graft 
occlusion 
1 (0·2%) 2 (0·3%) –0·1% –0·7–0·4 0·56 
Repeat revascularisation 7 (1·2%) 10 (1·7%) –0·5% –1·8–0·8 0·46 
Stroke 0 (0·0%) 4 (0·7%) –0·7% –1·3––0·01 0·04 
Re–operation for bleeding 1 (0·2%) 23 (3·9%) –3·7% –5·3––2·1 <0·0001 
Blood transfusion 11 (2·0%) 150 (27·5%) –25·4% –293 ––21·5 <0·0001 
Operation for sternum infection 0 (0·0%) 3 (0·5%) –0·5% –1·1–0·07 0·08 
Operation for access site complications 2 (0·4%) 4 (0·7%) 0·3% –1·2–0·5 0·41 
CT–verified pulmonary embolus 1 (0·2%) 1 (0·2%) 0·0% –0·4–0·9 0·99 
Duration of index treatment admission 2[1:4] 9[7:13]   <0·0001 
Table 3. Outcomes between index procedure and 30 days of follow–up by treatment group 
* Assessable in 45·1% of patients 625 
 626 
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 PCI CABG Risk difference 95% CI p–value 
MACCE 42 (7·1%) 42 (7·1%) 0·0 –2·9–2·9 1·00 
All–cause mortality 9 (1·5%) 17 (2·9%) –1·3% –3·0–0·3 0·11 
Cardiac death 8 (1·4%) 13 (2·2%) –0·8% –2·3–0·6 0·27 
Vascular death 0 (0·0%) 1 (0·2%) 0·1 –0·1–0·3 0·32 
Non–procedural MI 11 (1·9%) 8 (1·4%) 0·5% –0·9–1·9 0·49 
Revascularisation (total) 32 (5·4%) 24 (4·0%) 1·4% –1·1–3·8 0·27 
Symptomatic graft occlusion or definite stent 
thrombosis  
2 (0·3)% 7 (1·2%) –0·8% –1·8–0·1 0·09 
Stroke 2 (0·3%) 6 (1·0%) –0·7% –1·6–0·3 0·16 
Table 4. One–year clinical outcome by treatment group 
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Figure 1. Patient flow chart 635 
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Figure 2. Outcomes according to intention–to–treat 639 
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 35 
 642 
Figure 3. Outcomes by SYNTAX score group  643 
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Additional information regarding the trial “Percutaneous Coronary Angioplasty versus Coronary Artery 647 
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 771 
 772 
Data acquisition and monitoring 773 
Data were collected using a secure, web–based trial management system, Trialpartner, Institute of Clinical 774 
Medicine, Aarhus University Denmark. Remote monitoring was performed by Qmed Consulting ApS, 775 
Denmark, and by professional staff at Aarhus University Hospital, Denmark according to the monitoring 776 
plan specified before start of the monitoring process. Site visits were not performed systematically. 777 
Deidentified source material was transferred to the study organization at Aarhus University Hospital, 778 
Denmark by participating sites. Source material for the clinical event committee was monitored. In case the 779 
clinical endpoint committee requested additional documentation, this was requested from the sites, and the 780 
adjudication postponed to a subsequent meeting. 781 
  782 
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Clinical Endpoint Definitions 783 
 784 
All–cause mortality 785 
Death from any cause.  786 
 787 
Cardiac death  788 
Cardiac death was defined as any death due to a suspected cardiac cause (myocardial infarction, low–output 789 
heart failure, fatal arrhythmia), unwitnessed death and death of unknown cause. All procedure–related 790 
deaths, including those related to concomitant treatment, were classified as cardiac death. The endpoint was 791 
included post hoc. (Modified from Cutlip et al. Circulation. 2007;115:2344–2351) The information on cause 792 
of death was obtained from hospital patient files, from general practitioners, or from families if no other 793 
source was available. 794 
 795 
Vascular death 796 
Death caused by non–coronary vascular causes, including cerebrovascular disease, pulmonary 797 
embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular diseases. The endpoint was 798 
included post hoc. (Modified from Cutlip et al. Circulation. 2007;115:2344–2351) 799 
 800 
Non–procedure–related myocardial infarction 801 
A rise in biochemical markers exceeding the decision limit for myocardial infarction (99th percentile 802 
including < 10% CV) with at least one of the following; (1) ischemic symptoms, (2) ECG changes indicative 803 
of ischemia (ST segment elevation or depression), and (3) development of a pathologic Q–wave with no 804 
relation to a PCI procedure.  805 
 806 
Repeat revascularisation 807 
Any new PCI or CABG operation performed during follow–up. If an index revascularisation was attempted 808 
or successful, any subsequent revascularisation was counted as repeat revascularisation. Attempted PCI was 809 
defined as an advancement of a wire in the coronary tree at least. Attempted CABG was defined as at least 810 
initiation of an index operation.   811 
 812 
Procedure–related biomarker release 813 
The diagnosis of a procedure–related biomarker increase required a rise in total creatine kinase (CK) and/or 814 
Troponin–T/I. Due to the great heterogeneity of biomarkers and various assays used during the study in 815 
participating centres, this comparison was omitted from the final analysis.  816 
 817 
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Procedural myocardial infarction 819 
Diagnosis of procedural MI for both PCI and CABG patients was based on CK–MB elevations when 820 
available. Patients needed to have stable angina pectoris as the clinical indication OR a normal baseline CK–821 
MB, TnI, TnT, or highly sensitive TnT, to be assessable for procedural MI. Diagnosis required a CK–MB 822 
value above 10 x URL or ULN to establish the diagnosis. The diagnosis could also be placed by the 823 
combination of  a CK–MB value above 5 x URL or ULN, AND one or more of the following: (1) new 824 
pathological Q waves in at least 2 contiguous leads or new persistent non–rate–related left bundle branch 825 
block, or (2) angiographically documented graft or native coronary artery occlusion or new severe stenosis 826 
with thrombosis and/or diminished epicardial flow, or (3) imaging evidence of new loss of viable 827 
myocardium or new regional wall motion abnormality. The endpoint of procedural myocardial infarction 828 
was included post hoc and the definition was adapted to match the definition applied in the EXCEL trial on 829 
PCI vs. CABG for LMCA stenosis. Peri-procedural MI due to repeat revascularization during follow-up 830 
were assessed applying the 3rd Universal definition as CK-MB was not available in all event patients. A 831 
procedural MI according to this definition was counted as a non-index procedural myocardial infarction. 832 
 833 
 834 
Target lesion revascularisation 835 
Repeat revascularisation by PCI of any target segment treated during the index procedure. A target lesion 836 
segment was defined as a stented or balloon treated segment and its 5 mm margins.    837 
 838 
LMCA revascularisation 839 
Any subsequent revascularisation by PCI of the segments within 5 mm of any treated segment related to the 840 
LMCA or the LMCA bifurcation. Any revascularisation by CABG of native LMCA including the LMCA 841 
bifurcation, or revascularisation of a graft supplying the left anterior descending artery or circumflex arteries. 842 
 843 
Definite stent thrombosis 844 
Stent thromboses were categorized as acute, subacute, late and very late and as definite, probable and 845 
possible according to ARC criteria. (Cutlip et al. Circulation 2007;115:2344–51) 846 
 847 
Symptomatic graft occlusion 848 
Diagnosis of symptomatic graft occlusion required it to be detected during a clinically indicated coronary 849 
angiography. 850 
 851 
Stroke 852 
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Ischemic or haemorrhagic cerebrovascular event verified by brain computed tomography (CT) or magnetic 853 
resonance imaging (MRI).  854 
 855 
Pulmonary embolus 856 
The diagnosis of pulmonary embolus required verification by an appropriate computed tomography scan. 857 
 858 
NYHA class and CCS class Patients were queried yearly by telephone regarding symptoms of angina 859 
pectoris and heart failure; if they reported angina, they were categorized as Canadian Cardiovascular Society 860 
(CCS) classes 1 through 4. If they reported heart failure symptoms, they were categorized as New York 861 
Heart Association (NYHA) functional classes 1 through 4 862 
 863 
Recommendations for angiography and re–revascularisation 864 
Re–angiography was indicated by the presence of new symptoms of angina pectoris or new onset of acute 865 
coronary syndrome, angina pectoris Canadian Cardiovascular Score class >2, heart failure or severe 866 
tachyarrhythmia (ventricular fibrillation or ventricular tachycardia). Revascularisation was indicated if a 867 
stenosis exceeded a diameter stenosis of 70% by visual assessment or if fractional flow reserve was 868 
measured and had a value below 0·75. 869 
 870 
Classification of left main coronary artery stenosis 871 
Distal LMCA lesions were bifurcation lesion involving the left anterior descending artery and/or left 872 
circumflex artery. Ostial LMCA lesions were defined as lesions with or without shaft involvement and no 873 
distal bifurcation involvement. Shaft lesions were lesions limited to the shaft without involvement of the 874 
LMCA ostium and the LMCA bifurcation. 875 
 876 
Sample size calculation and primary endpoint reporting 877 
The sample size calculation was based on the combined primary endpoint of death, stroke, non–index 878 
treatment related MI and new revascularisation (PCI or CABG) after 2 years.  879 
The study was planned as a non–inferiority study, where PCI was considered the experimental treatment of 880 
LMCA disease and was compared to CABG as the standard treatment. PCI was not allowed to be more than 881 
clinically insignificantly inferior to CABG to be declared non–inferior. Calculations were based on the 882 
following: 883 
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• mean follow–up time of 24 months 884 
• all event curves being exponential 885 
• zero dropout  886 
• randomisation into 2 equally sized groups 887 
• α = 0·05 (one–sided) 888 
• 1– β (power) = 80% 889 
The non–inferiority limit was based on a 12–month MACCE rate of 12% in the CABG group and 16% in the 890 
PCI group (the SYNTAX study). With exponential event curves (CABG(t)=exp(–λ*t)), this corresponded to 891 
a hazard ratio of 1·36 for PCI versus CABG and, with t in months, λ=0·0107 in the CABG group. In line 892 
with the SYNTAX study, the present study used a hazard ratio of 1·35 for PCI versus CABG, as the limit for 893 
non–inferiority, and λ=0·011 to describe MACCE in the CABG group. These figures corresponded to 24–894 
month MACCE rates of 30% and 23% in the PCI and CABG groups, respectively. The above preconditions 895 
and assumptions resulted in the number of patients needed in each randomisation group equalling 593 (and a 896 
total number of events – in both groups – equalling 275). Consequently, 1186 patients needed to be 897 
randomised. It was decided to include 600 patients in each group to account for possible dropouts before 898 
follow–up and for estimation errors. 899 
Protocol change of January 22, 2015 900 
Due to lower than expected endpoint rates, the total number of events needed to assess inferiority would not 901 
be reached within a fixed two–year follow–up period. Determining if the primary endpoint of non-inferiority 902 
by PCI was met would likely be inconclusive. The response was carefully considered by investigators and 903 
statisticians. To accommodate, the total follow–up time of up to five years for each patient was included in 904 
the primary endpoint calculation. The time point for assessment was defined as when reaching a total of 275 905 
primary endpoint events corresponding to a median 3.7 years (at the time).   906 
Change in primary outcome reporting 907 
September 2015. Due to changes in forecasting it was estimated that 275 primary endpoint events would not 908 
be reached within the full 5–year follow–up period. Statistical support was consulted and at the investigator 909 
meeting at TCT in San Francisco on October 12, 2015, it was decided to report the primary outcome based 910 
on a median 3–year follow–up (effective follow-up time was median 3.1 years) commencing collection of 911 
events for the primary endpoint until May 1st, 2016.  Options regarding the primary endpoint were the 912 
following: (1) to return to the full two-year endpoint, accepting that the study would be vastly underpowered 913 
for assessing whether non-inferiority was met and that the study would likely be inconclusive; (2) to await 914 
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the full 5 years of follow-up, available in 2020, still not reaching the prespecified number of events; or (3) 915 
reporting results both after a median of three years of follow-up, based on roughly 75% of the total number 916 
of expected events occurring within the full five-year follow-up, and then again after reaching the full five-917 
year follow-up to confirm the estimates. The third option allowed to determine with confidence whether non-918 
inferiority was met after a median of 3 years of follow-up, based on the predefined hazard ratio, without 919 
withholding these important results for another almost 4 further years. 920 
Data safety monitoring committee (DSMC) 921 
The safety of the study was monitored by an independent Data and Safety Monitoring Committee (DSMC) 922 
headed by Prof. Juha Hartikainen, Kuopio University Hospital, Finland. The DSMC received information on 923 
rates of all–cause mortality, non–index procedure–related myocardial infarction, definite stent thrombosis, 924 
target lesion revascularisation and stroke. The DSMC made independent decisions on continuation or 925 
stopping the study. Termination of the study was to be recommended if at any time a significant difference 926 
(p–value of < 0·003 by χ2–test) was found between rates of all–cause mortality, non–index procedure–927 
related myocardial infarction definite stent thrombosis, target lesion revascularisation or stroke. 928 
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LMCA stenting involving ostium and not bifurcation 59 (10·2%) 
Shaft LMCA stenting only  11 (1·8%) 
LMCA bifurcation lesion stenting  508 (87·7%) 
   Angulation less than 70 degrees* 110 (22·3%) 
   Visible calcification* 213 (42·5%) 
   Severe tortuosity* 55 (10·8%) 
   Stenting of LMCA–LAD only* 300 (59·4%) 
   Stenting of LMCA–Cx only* 21 (4·2%) 
   Culotte*  119 (23·9%) 
   Crush* 20 (4·0%) 
   T–stenting* 41 (8·4%) 
   V–stenting* 1 (0·2%) 
   Other technique* 4 (0·8%) 
Total stent length in LMCA lesion (mm) 24 [IQR 15:35] 
Total number of stents in LMCA lesion (n) 1 [IQR 1:2] 
IVUS pre–evaluation 270 (46·8%) 
IVUS post–evaluation 430 (74·9%) 
Pre–dilatation of LMCA 498 (86·6%) 
Pre–dilatation of LAD* 426 (76·9%) 
Pre–dilatation of Cx* 204 (40·8%) 
Post–dilatation of LMCA 515 (89·7%) 
Post–dilatation of LAD* 249 (53·4%) 
Post–dilatation of Cx* 399 (79·8%) 
Max pressure of largest balloon in LMCA 18 [IQR 16:20] 
Max pressure of largest balloon in treated LAD 18 [IQR 14:20] 
Max pressure of largest balloon in treated Cx 16 [IQR 12:18] 
 49 
Nominal diameter of largest balloon or stent in LMCA 4·0 [IQR 4·0:4·5] 
Nominal diameter of largest balloon or stent in treated 
LAD 
3·5 [IQR 3·5:4·0] 
Nominal diameter of largest balloon or stent in treated 
Cx 
3·0 [3·0:3·5] 
Kissing balloon post inflation* 277 (54·5%) 
Number of treated lesions  
  1  312 (53·4%) 
  2  191 (32·5%) 
  3  55 (9·6%) 
  4  14 (2·4%) 
  5  3 (0·5%) 
Total stent length in non–LM lesions if treated (mm) 28 [IQR18:42] 
Total number of stents in non–LM lesions if treated 1 [1:2] 
Procedure time (min) 62 [IQR 47:85] 
Fluoroscopy time (min) 26 [IQR 11:24] 
Contrast volume (mL) 200 [IQR 150:280] 
Complete revascularisation 543 (94·1%) 
LMCA treated by 1st generation drug–eluting stent   42 (10·9%) 
Antithrombotic treatment  
Unfractionated heparin 411 (72·6%) 
Low molecular weight heparin 81 (14·2%) 
Bivalirudine 108 (18·9%) 
GPIIbIIa inhibitor 110 (19·1%) 
Aspirin 539 (92·9%) 
Clopidogrel/Ticlopidine/Ticagrelor 566 (97·4%) 
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Table S1. Treatment characteristics in the PCI group 
 930 
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On–pump technique 476 (84·4)% 
Off–pump technique 88 (15·6%) 
Arterial graft  532 (94·5%) 
Arterial graft to LAD 526 (93·4%) 
LIMA + RIMA grafts 44 (7·9%) 
LIMA + venous graft 480 (85·7%) 
Radial artery graft 26 (4·8%) 
Venous grafts only 27 (5·0%) 
Grafts per patient  
  1 23 (4·1%) 
  2 294 (52·0%) 
  3 220 (39·0%) 
  4 25 (4·4%) 
  5 3 (0·6%) 
Table S2. Treatment characteristics in the CABG group 
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